The discovery of classic epidermal growth factor receptor (EGFR)-activating mutations more than a decade ago changed the treatment landscape for patients with metastatic non-small cell lung cancer (NSCLC) [1,2]. Here, EGFR is linked to non-small cell lung carcinoma.